LLY · earnings call history
Eli Lilly Q2 FY26 — Strong Revenue Growth and Pipeline Advancement
Read the briefEli Lilly Q1 FY26 — Strong Growth Driven by Incretins and Foundayo Launch
Read the briefEli Lilly Q4 FY25 — Robust Growth Driven by Key Products and Pipeline Expansion
Read the briefEli Lilly Q3 FY25 — Strong Growth Across Key Products and Raised Guidance
Read the briefEli Lilly and Company Q2 FY25 — Strong Growth, Pipeline Progress, and Raised Guidance
Read the briefEli Lilly and Company Q1 FY25 — Strong Growth Driven by Key Products and Positive Oral GLP-1 Data
Read the briefEli Lilly Q4 FY24 — Strong Incretin Growth and Pipeline Advancement
Read the briefBrowse all US companies on the earnings-call register.